Since 2013, substantial scientific research has evaluated the effectiveness of micronutrient supplementation in managing eye floaters.
The most recent Floater Intervention Study (FLIES) stands out as particularly significant. Not only did it show improvements in subjective visual disturbance scores and improved visual function, but researchers also utilized the ultra-widefield imaging module of the SPECTRALIS HRA + OCT from Heidelberg Engineering GmbH to capture a 30-second, 102° field, cross-polarized infrared reflectance video of the vitreous. From this video, five still images of eye floaters were extracted, making the areas of vitreous opacities visible. After 6 months, objective improvement of eye floaters was proven in 77% of patients.
Explore this page to discover everything about the tested micronutrient VitroCap®N—its mechanism of action, clinical feedback, and instructions for ordering samples or stocking it in practice shops, and more.
After 6 months, objective improvement of eye floaters was proven in 77% of patients. Fill out the form to receive the complete study data via email.
The vitreous body has a unique protective mechanism against oxidative stress and collagen glycation. However, this mechanism loses efficacy during degeneration. Providing the eye with naturally occurring micronutrients can help reactivate this mechanism, minimising or even preventing collagen fibres from clumping. The healthy vitreous exhibits notably high concentrations of micronutrients, including:
Other micronutrients are known to effectively combat oxidative stress and protein glycation:
Incorporating these micronutrients through supplementation with VitroCap®N may potentially slow down or even reverse, the progression of floaters. The effectiveness of this approach has been demonstrated in five clinical trials.
Did you know that eye care professionals can request free samples of VitroCap®N here?
Nutritional information | Per capsule = Recommended daily intake | Percentage of reference intake per capsule* |
|---|---|---|
Zinc | 5 mg | 50% |
Vitamin C | 40 mg | 50% |
Grape seed extract | 26,3 mg | ** |
– of which proanthocyanidins | 25 mg | ** |
Citrus fruit extract | 100 mg | ** |
– of which citrus flavonoids (hesperidin) | 60 mg | ** |
L-Lysine | 125 mg | ** |
* Percentage of the reference intake per EU Regulation 1169/2011
** no nutrient reference values available / no recommendation available in the EU
Gluten-free, lactose-free, made in Europe
The recommended dosage is one capsule per day with a little liquid after a meal for an initial period of at least 3 to 6 months. Continuing use beyond this period should be tailored to your individual needs.
In the Floater Intervention Study (FLIES), researchers used the ultra-widefield imaging module of the SPECTRALIS HRA + OCT from Heidelberg Engineering GmbH to capture a 30-second, 102° field, cross-polarised infrared reflectance video of the vitreous. Patients were asked to move their gaze in various directions, returning to a central fixation point after each movement. From the video, five still images of eye floaters were extracted, each from a different angle.
The vitreous opacity outlines were manually delineated using a ‘freehand selection‘ tool, and the areas of opacity were calculated for each image. These individual areas were then combined to provide a total measurement, reported in square centimetres.
Did you know?
The FLIES study is the first randomised, double-blind, placebo-controlled clinical trial to assess the impact of targeted nutritional supplementation on vitreous floaters. The trial included 61 patients aged 18-79 years. After 6 months of supplementation with VitroCap®N, 77% of patients experienced a reduction in vitreous opacity areas.
The assessment of symptoms caused by vitreous opacities is usually performed using subjective questionnaires. However, there is currently no uniform, standardized tool for classifying and quantifying the visual impairments caused by floaters.
To improve the diagnosis and monitoring of these symptoms, we are providing you with the validated questionnaire from the Floater Intervention Study (FLIES) for download. The placebo-controlled, double-blind FLIES study was conducted in 2021 at the Nutrition Research Centre Ireland (NRCI) – an independent, multidisciplinary research center specializing in studying the effects of nutrition and lifestyle on health.
As part of the study, participants completed the questionnaire before and after a six-month intake of VitroCap®N. The analysis showed that visual disturbances significantly improved in 67% of patients after six months of treatment with VitroCap®N.
The FLIES questionnaire enables a structured assessment of symptoms and can help reliably evaluate individual treatment success. You can download the questionnaire either as a fillable PDF for your patient records or as a print version for hard copies. Page two contains extended patient information. This makes the questionnaire suitable for early completion in the waiting room or for regular monitoring at home.
VitroCap®N has been on the market for over 10 years, with eye care professionals across Europe gathering valuable clinical experience. These experts have shared their insights, contributing to a broader understanding of the supplement’s impact. In discussions and contributions from both internationally and nationally renowned physicians and researchers, the latest findings on vitreous degeneration were explored, including its effects on visual function and quality of life.
See the full discussion on YouTube.
The videos from the symposium can be found here.
A big thank you to Martin Oguzie from the YouTube channel “Martin the Optometrist” for this incredible, self-driven work. In his video, Martin takes a thoughtful deep dive into VitroCap®N as a solution for eye floaters. He goes above and beyond — thoroughly researching, reviewing multiple sources, and creating a clear, well-structured video enriched with his own clinical insights and outtakes from a symposium.
For full transparency: Martin is not affiliated with VitroCap®N, ebiga-VISION, or VivaQuity in any commercial way. As he himself puts it: “It’s important to me to remain unbiased — because the floater community expects and deserves that.”
Research Team | Year | Duration | Design | Success Rate | Link |
|---|---|---|---|---|---|
Ankahmah et al | 2021 | 6 months | RCT (double-blind) | 66.7% | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525826/ |
Varganova et al. | 2019 | 3 months | Case-control study | 76% | https://journals.eco-vector.com/ov/article/view/11875 |
Sobol et al. | 2018 | 3 months | Observational study | 64.7% | https://www.researchgate.net/publication/326345092 |
Marchencko et al. | 2015 | 3 months | Case-control study | 65.5% | https://ebiga-vision.com/marchencko-et-al.pdf |
Kaercher et al. | 2013 | 3 months | Observational study | 87.5% | https://ebiga-vision.com/ZPA_9-2023-eye-floater-symposium |
ebiga-VISION aims to give you the opportunity to assess the product yourself, provide your patients with comprehensive and straightforward advice, and offer them an evidence-based option for the management of floaters.
Please contact us using our contact form. We would be happy to send you a PDF with our current prices and discount levels for practice shop owners. You can also easily reach us by phone to place an order.
In most countries, patients can conveniently order VitroCap®N from selected pharmacies or trusted online retailers. It is also available through the official distributor, ebiga-VISION, and their authorized partner shops. Simply click on your country flag to be redirected to the relevant shop page.
Leave a brief message and a member of ebiga-VISION will contact you as soon as possible
